Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy

SGLT2 inhibitors (SGLT2i) are glucose‐lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of glucosuri...

Descripción completa

Detalles Bibliográficos
Autores principales: Westcott, Gregory P., Segal, Alissa R., Mitri, Joanna, Brown, Florence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170458/
https://www.ncbi.nlm.nih.gov/pubmed/32318635
http://dx.doi.org/10.1002/edm2.117
Descripción
Sumario:SGLT2 inhibitors (SGLT2i) are glucose‐lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of glucosuria and inpatient course of SGLT2i‐related DKA, however, is not well‐characterized. We report 11 inpatient cases of SGLT2i‐related DKA, including a subset of patients who experienced prolonged glucosuria and relapse of DKA during their hospitalization.

Ejemplares similares